A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT06718634
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT06718621
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06668961
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06612840
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06609187
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06598787
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT06505824
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06503783
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Ha'erbin, Heilongjiang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 652
- Registration Number
- NCT06500026
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06500052
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
© Copyright 2024. All Rights Reserved by MedPath